Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
NCT03684980Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2018
- Primary completion
- Nov 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glucarpidase in central nervous system lymphoma (5 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients that have significant reduction of serum methotrexate levels at 1 year. Started Nov 2018; status: active, not recruiting.
02
Drugs
glucarpidase
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT03684980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684980.